“In 2023, we took significant steps to reposition our organization, renew our focus on value creation, and advance our efforts to bring transformational medicines to patients around the world,” said Dr. Paul Stoffels, CEO and Chairman of the Board of Directors of Galapagos. “Following the successful transfer of the Jyseleca business last month, we are moving forward with a streamlined portfolio and enhanced focus on our differentiated and innovative pipeline. We are determined to generate sustainable, long-term value for our shareholders, our patients, and our employees.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GLPG:
- GLPG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Galapagos completes transfer of Jyseleca business to Alfasigma
- Galapagos enters GMP manufacturing agreement with Thermo Fisher
- Galapagos collaborates with BridGene Biosciences for small molecule drugs
- BridGene in $27M collaboration and licensing pact with Galapagos
